拓扑替康联合白介素-2治疗恶性浆膜腔积液的近期疗效观察  

Observation of Topotecan Combined with Interleukin-2 in the Treatment of Patients with Malignant Serous Effusion

作　　者：易全会 任章霞[1] 

机构地区：[1]广安市人民医院,四川广安638000

出　　处：《川北医学院学报》2009年第5期446-447,共2页Journal of North Sichuan Medical College

摘　　要：目的观察拓扑替康联合白介素-2治疗恶性浆膜腔积液近期疗效及耐受性。方法经病理组织学及细胞学检查证实的32例恶性浆膜腔积液病例,均采用经皮中心静脉导管浆膜腔内置入引流,引流干净后腔内灌注拓扑替康及白介素-2。结果浆膜腔积液控制率约84.4%,毒副作用轻。结论拓扑替康联合白介素-2治疗恶性浆膜腔积液近期疗效好,毒副作用轻,耐受性好。Objective To observe the efficacy and tolerance of the combination of topotecan and interleukin-2 for malignant serous effusion patients. Methods 32 patients histologically and cytologically conformed malignant serous effusion received the treatment of the combination of topoteean and interleukin-2 by thoracic infusion after drainage the effusions by pereutaneous transluminal placement of central venous catheter. Results The disease controlled rate is 84.4% and the toxicities is tolerable. Conclusions The efficacy of the combination of topotecan and interleukin-2 for malignant serous effusion patients is good, adverse effect is wild and torlerable.

关 键 词：拓扑替康 白介素-2 恶性浆膜腔积液 

分 类 号：R541.9[医药卫生—心血管疾病]